|Bid||4.11 x 2200|
|Ask||0.00 x 1300|
|Day's Range||8.35 - 8.81|
|52 Week Range||0.20 - 11.25|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 27, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace.
DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a pioneer in the global digital therapeutics market, today presented a new clinical study at the Advanced Technologies & Treatments for Diabetes ("ATTD") conference in Madrid, Spain, which showed significant reductions of both hypoglycemic and high glycemic events in people with type 1 and insulin dependent type 2 diabetes using Dario's digital therapeutics platform. The presentation will be available at the conference, on the ATTD 2020 website during the conference, and online for one year following the conference. The accepted abstract will be published in the peer-reviewed journal Diabetes Technology & Therapeutics.
DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today that on January 30, 2020, Richard Anderson was granted a non-qualified stock option award to purchase 90,000 shares of the Company's common stock, as well as an additional non-qualified performance-based stock option award to purchase an additional 90,000 shares of the Company's common stock, pursuant to Nasdaq Listing Rule 5635(c)(4) outside of the Company's existing equity compensation plans in connection with Mr. Anderson's previously-announced employment by the Company as its President and General Manager of North America. These options were granted as an inducement material to Mr. Anderson becoming an employee of the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).
DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today the appointment of Richard Anderson as its President and General Manager of North America, effective January 13, 2020. Reporting to Chief Executive Officer Erez Raphael, Mr. Anderson will be responsible for both operational and commercial development, focusing primarily on the U.S. market. His appointment marks a key inflection point, supporting DarioHealth's strategic initiatives in the business-to-business (B2B) channel. This is one of many organizational changes that emphasize our focus on this large market. In conjunction with Mr. Anderson's appointment, DarioHealth will transition Olivier Jarry to serve as Senior Vice President of Strategy and Business Development.
DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today that it has closed on a private placement of convertible preferred stock to institutional and private investors. The Company received aggregate gross proceeds of approximately $21.3 million, before deducting placement agent fees and other offering expenses payable by the Company.
Monday ended up being a non-starter thanks to a snowstorm that kept me from my regular trading station at Warrior Trading HQ. Despite that, Tuesday ended up being a stellar day that boosted my account by 40% thanks to one really strong position in DarioHealth Corp. (NASDAQ: DRIO). DRIO was the second leading stock on my morning gap scanner that day, up about 80%.
Shares of digital health company DarioHealth Corp (NASDAQ: DRIO ) are advancing strongly Tuesday. DarioHealth said its Dario-powered digital diabetes app has been launched on Walmart Inc's (NYSE: WMT ) ...
Shares of DarioHealth Corp. jumped 103% as it announced that Walmart would sell DarioHealth's digital diabetes management system online. The company has established online partnerships with other retailers like Best Buy and Giant Eagle, a privately owned grocery chain. "In addition to Best Buy, we expect to announce our products in several of the top five retailers in the U.S." DarioHealth president and chief commercial officer Olivier Jarry told investors in October, according to a FactSet transcript of the third-quarter earnings call. "These retailers have told us that launching online is a natural stepping stone for them before planning to launch in their brick-and-mortar stores." DarioHealth's stock has fallen 67% year-to-date. The S&P 500 has gone up 24% during the same time period.
Global digital therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO) announced today the launch of the Dario-powered digital diabetes program on Walmart.com.
Global digital therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), announced today that its online membership offering will now be available for purchase in physical retail stores. The "Membership-in-a-Box" (MIB) package was designed to reach consumers with chronic conditions such as diabetes who shop at retail stores. This concept, started in partnership with Best Buy Online in the U.S., is now planned to expand to other retail chains. Prior to this expansion, retail stores only sold the Dario blood glucose meters, strips and other supplies. This is another move by Dario with the goal and potential to generate recurring revenues consistent with its high-margin, software as a service (SAAS) based model.
- Based on data collected from active users, Dario proves digital interventions can play a key role in management of chronic conditions like diabetes - 45% of the study group reduced their average blood ...
- DarioHealth CEO Joins Digital Health Industry Innovators panel in discussion on the need for clinical evidence CAESAREA, Israel and NEW YORK , Nov. 14, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: ...
SAN JOSE, California and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader, DarioHealth Corp. (DRIO) announced today the launch of a Dario-powered digital diabetes program with Action Urgent Care. Action Urgent Care has experienced rapid growth since its first clinic opened in San Jose in 2013, to more than 40 points of care they operate throughout California today. The clinics offer a broad range of services including walk-ins for immediate care, primary care, specialized medicine, physical exams, diagnostics, preventative screenings and immunizations.
Erez Raphael has been the CEO of DarioHealth Corp. (NASDAQ:DRIO) since 2013. First, this article will compare CEO...
NEW YORK, NY / ACCESSWIRE / October 28, 2019 / DarioHealth Corp. (NASDAQ: DRIO ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 28, 2019 at 9:00 AM ...
NEW YORK and CAESAREA, Israel , Oct. 28, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported financial and operational results for the third quarter ...
CAESAREA, Israel and NEW YORK, Oct. 22, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, has appointed Dr. Abigail Hirsch to its Advisory Board where she will help guide commercial and Business-to-Business (B2B) efforts. Dr. Hirsch has many years of experience utilizing clinical psychology, data analytics and educational design to create innovative healthcare technology that helps people lead healthier, more fulfilling lives. Prior to joining Dario, Dr. Hirsch served as Chief Clinical Officer at a behavioral health company called myStrength, helping lead the company from inception through its acquisition by Livongo Health, Inc. in the first quarter of 2019.
Earnings Discussion and Business Update Scheduled for 9:00 am EDT NEW YORK and CAESAREA, Israel , Oct. 17, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: ...
NEW YORK and CAESAREA, Israel, Sept. 23, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, today announced that Erez Raphael, DarioHealth's Chief Executive Officer, will be a speaker at the second annual DTx East 2019 conference taking place at Harvard Medical School in Boston, MA from September 24-26, 2019. DTx East provides a forum for key decision makers and innovators in the rapidly expanding digital therapeutics industry to network, learn and share ideas. The three-day conference provides a meeting point for more than 300 senior leaders from a range of digital therapeutic companies, including pharmaceutical companies, investors, payers and health care providers.
NEW YORK and CAESAREA, Israel, Sept. 18, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office titled "Systems and Methods for Enabling Optical Transmission of Data Between a Sensor and a Smart Device." The patent will allow Dario to develop paired smartphone devices that can collect and analyze real-time medical data and provide immediate and highly detailed, personalized data reports to the user. Once collected, this data can be shared with healthcare providers through the DarioEngage™ platform to facilitate digital health interventions based on the data analysis. "Dario's business and product strategy is guided by evidence that shows that increased user engagement and direct empowerment of individuals to manage their personal health leads to better medical outcomes," said Erez Raphael, DarioHealth's chief executive officer.
DURHAM, North Carolina and NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced today it has formed a strategic alliance with DarioHealth Corp. "Dario" (DRIO), a leading, global digital therapeutics company, to expand access to a personalized digital health management platform for patients with chronic diseases. Under the terms of the agreement, Dance Biopharm will integrate its gentle mist smart inhaler into DarioHealth's digital therapeutics platform to provide patients automated, real-time treatment data through an advanced mobile application.
NEW YORK and CAESAREA, Israel , Aug. 28, 2019 /PRNewswire/ -- Leading global digital therapeutics company DarioHealth Corp. (Nasdaq: DRIO) today announced that DarioHealth's Chief Executive Officer, Erez ...